Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

Inclusion Criteria:

• Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial
• Patients who have provided informed consent for the long-term follow-up study

Exclusion Criteria:

• None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.